| Returns | 1W : 5.4% , 1M : 0.7%,1Y : 64% |
| LT : |
Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| LINCOLN PHARMACEUTICALS | 5.4% | 0.7% | 64% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.4% | 6.4% | 39.2% |
| DR REDDYS LABORATORIES | -0.4% | 11.7% | 26.7% |
| DIVIS LABORATORIES | 0.6% | 12.6% | 59.7% |
| CIPLA | 4.8% | 19.4% | 56.3% |
| BIOCON | 0.6% | 3.5% | 18% |
| AUROBINDO PHARMA | 5.4% | 14.8% | 74.8% |
| LUPIN | 1.5% | 0.6% | 27.8% |
| TORRENT PHARMACEUTICALS | 1.6% | 5% | 12.5% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
9.65
P/E Calculated based on EPS of 24.78
[ Mar2020 - Standalone Results ] 1.57
P/B Calculated based on Book Value of 152.25
[ Mar2020 - Standalone Results ] 1.25
P/S Calculated based on Revenues of 382.532 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
1% -9% 4% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 2.5% | 9.5% | 53.4% |
| S&P BSE MIDSMALLCAP | 0.6% | -2.9% | 87.1% |
| S&P BSE SMALL CAP | 0.6% | -2.3% | 99.4% |
| S&P BSE ALLCAP | 0.5% | -3.5% | 67.3% |
